Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics' stock has shown a significant increase of +142.14% over the last year, although it has fallen by -13.12% in the past month and -0.41% in the previous week as of January 11, 2026. The company executed a 1:240 reverse stock split on December 29, 2023. Avalo Therapeutics is scheduled to release its next earnings report on March 26, 2026. For the last quarter, the company reported earnings of -2.19 USD per share, missing the estimation of -1.66 USD by -32.06%. Revenue for the last year amounted to $882,000, with a net income of -$70.26 million. Avalo received $69.4 million from the full exercise of private placement warrants and an additional $58.1 million from the exercise of warrants issued in early 2024, which are expected to support operations into at least 2027, and potentially into 2028. Investor confidence has been impacted by the progress of AVTX-009, with a notable pre-market increase in stock price due to anticipation of the LOTUS trial data readout. Analysts have provided a consensus rating of "Moderate Buy" or "Strong Buy" for AVTX, with an average price target suggesting a significant upside potential.

Specific data on demand seasonality for Avalo Therapeutics, Inc.'s products and services is not readily available. Given that the company is primarily a clinical-stage biotechnology firm with products in various trial phases or early commercialization, traditional demand seasonality may not be a significant factor. The demand for its products would likely be driven by clinical trial outcomes, regulatory approvals, and the prevalence of the diseases it aims to treat.

Avalo Therapeutics, Inc. is a clinical-stage precision medicine company focused on discovering, developing, and commercializing targeted therapeutics for patients with unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. The company's pipeline includes AVTX-009, a humanized monoclonal antibody targeting interleukin-1β (IL-1β) in Phase 2 trial for hidradenitis suppurativa (HS); AVTX-002 (formerly quisovalimab), a fully human anti-LIGHT monoclonal antibody undergoing Phase II and III clinical trials; AVTX-007, a fully human Anti-IL-18 monoclonal antibody in Phase I clinical trial for Still's disease; AVTX-801, a D-galactose substrate replacement therapy in Phase III clinical trials for phosphoglucomutase 1 deficiency (PGM1); AVTX-803, an L-fucose substrate replacement therapy in Phase III clinical trials for LADII; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. The company also offers dietary supplements such as chewable tablets and drops. Avalo Therapeutics was incorporated in 2011 and was formerly known as Cerecor Inc., changing its name in August 2021.

Avalo Therapeutics, Inc. is headquartered in Rockville, Maryland, United States, with an additional presence in Wayne, Pennsylvania. The company's operations are primarily focused within the United States.

Avalo Therapeutics has generally received positive sentiment from analysts in the past year, with a consensus rating of "Moderate Buy" or "Strong Buy". Mizuho initiated coverage with an "outperform" recommendation in December 2025, and BTIG and Jefferies have also reiterated or initiated "Buy" recommendations. Concerns have been raised regarding the safety profile of AVTX-009, with reports of neutropenia in some cases during trials. Competitive challenges from other treatments and the historically low diagnosis and treatment rates in relevant patient populations are noted as potential hurdles. The company's financial challenges, including declining revenues and persistent losses, have also been highlighted, though positive technical indicators and strategic corporate events offer some optimism.

Institutional shareholders hold 84.47% of Avalo Therapeutics' stock, while Avalo Therapeutics insiders hold 448.11%, and retail investors hold 0.00%. Major institutional owners include Armistice Capital LLC, BVF Inc/il, Orbimed Advisors Llc, Nantahala Capital Management, LLC, Point72 Asset Management, L.P., Affinity Asset Advisors, LLC, Caligan Partners LP, Balyasny Asset Management Llc, Vanguard Group Inc, and RA Capital Management, L.P. Notable individual insiders include Robert Moscato Jr. and Randal Jones. Insider transactions in the past three months have shown only sales, with no reported buys.